Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreBringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreAccelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTSThe Inflation Reduction Act includes drug price negotiation as a key component. Whether drugs were selected for negotiation in 2023 or will be chosen in the future, their impact will be significant, especially in therapeutic areas affected by negotiation. Manufacturers are proactively assessing risk and preparing for the margin impact resulting from negotiation.
James Brown
Vice President, U.S. Market Access Strategy Consulting, IQVIA
Rob Glik
Vice President and GM, Value & Access Strategy Consulting, IQVIA
Gain high value access and increase the profitability of your brands